Research and Markets (http://www.researchandmarkets.com/research/t6tvfm/hypercholesterolem) has announced the addition of the "Hypercholesterolemia - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Hypercholesterolemia Overview
- Therapeutics Development
- Pipeline Products for Hypercholesterolemia - Overview
- Pipeline Products for Hypercholesterolemia - Comparative Analysis
- Hypercholesterolemia - Therapeutics under Development by Companies
- Hypercholesterolemia - Therapeutics under Investigation by Universities/Institutes
- Hypercholesterolemia - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Hypercholesterolemia - Products under Development by Companies
- Hypercholesterolemia - Products under Investigation by Universities/Institutes
- Hypercholesterolemia - Companies Involved in Therapeutics Development
- 3SBio Inc.
- Abeome Corporation
- Aegerion Pharmaceuticals, Inc.
- Amgen Inc.
- AtheroNova Inc.
- BioLingus AG
- Catabasis Pharmaceuticals, Inc.
- Cerenis Therapeutics Holding SA
- CymaBay Therapeutics, Inc.
- Daewon Pharm Co. Ltd.
- DreamPharma Corp.
- Dybly AG
- Eli Lilly and Company
- Esperion Therapeutics, Inc.
- F. Hoffmann-La Roche Ltd.
- Gemphire Therapeutics Inc.
- Hanmi Pharmaceuticals, Co. Ltd.
- Immune Response BioPharma, Inc.
- Johnson & Johnson
- Kadmon Corporation, LLC
- Kowa Company, Ltd.
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
- RegenxBio Inc.
- Sanofi
- Serometrix, LLC
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- The Medicines Company
- Thetis Pharmaceuticals LLC
- Viking Therapeutics, Inc.
- Zhejiang Hisun Pharmaceutical Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/t6tvfm/hypercholesterolem
View source version on businesswire.com: http://www.businesswire.com/news/home/20160122005558/en/
